Together with our previously published studies showing that imatinib can successfully block PDGFR-α on the BBB and thereby significantly reduce the stroke volume [9], we now provide evidence that imatinib is also a potent agent when used as a therapy against CNS inflammatory diseases such as MS. This evidence concerns the gene PDGFRA and myeloid sarcoma.